Techniques and complications of transaortic subvalvular myectomy in patients with hypertrophic obstructive

H D Schulte1, W Bircks, B Lösse

  • 1Department of Thoracic and Cardiovascular Surgery, University of Düsseldorf, F.R.G.

Zeitschrift Fur Kardiologie
|January 1, 1987
PubMed

Insights

Transaortic subvalvular myectomy (TSM) is a safe surgical option for hypertrophic obstructive cardiomyopathy (HOCM) patients unresponsive to medication. While TSM alone has low mortality, additional procedures increase risks, though clinical improvement is noted.

Area of Science:

  • Cardiology
  • Cardiac Surgery

Background:

  • Hypertrophic obstructive cardiomyopathy (HOCM) natural history includes mitral insufficiency, congestive heart failure (CHF), and sudden death.
  • Medical therapy (beta-blockers, calcium-antagonists) may fail in NYHA class III patients.
  • Surgical intervention is considered for refractory HOCM.

Purpose of the Study:

  • To evaluate the safety and efficacy of transaortic subvalvular myectomy (TSM) for HOCM.
  • To analyze outcomes based on whether TSM was performed alone or with additional procedures.

Main Methods:

  • Retrospective analysis of 212 HOCM patients undergoing surgery between 1963 and 1986.
  • Surgical procedures included transaortic subvalvular myectomy (TSM), with or without mitral valve replacement (MVR) and other interventions.

Main Results:

  • Overall hospital mortality was 6.6%.
  • Mortality for TSM alone was 3.8% (160 patients).
  • Mortality increased to 15.4% for patients requiring additional procedures (52 patients), particularly with MVR.

Conclusions:

  • TSM is a low-risk surgical procedure for HOCM with good short-term outcomes.
  • Concomitant procedures significantly increase surgical risk.
  • Postoperative subjective and hemodynamic improvements are evident, but long-term survival and sudden death reduction require further study.

Related Concept Videos

Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...